Brief: X4 Pharmaceuticals Announces Positive Phase 3 Results For Mavorixafor

X4 Pharmaceuticals

16/05/2023 21:18

May 16 (Reuters) - X4 Pharmaceuticals Inc  XFOR.O :
    * X4 PHARMACEUTICALS ANNOUNCES POSITIVE PHASE 3 RESULTS
SHOWING
MAVORIXAFOR REDUCED THE RATE, SEVERITY, AND DURATION OF
INFECTIONS VERSUS. PLACEBO IN PARTICIPANTS DIAGNOSED WITH WHIM
SYNDROME
    * X4 PHARMACEUTICALS INC - ON TRACK TO SUBMIT NDA FOR
MAVORIXAFOR
EARLY IN 2H 2023 FOLLOWING COMPLETION OF PRE-NDA MEETING WITH
FDA
    * X4 PHARMACEUTICALS INC - ABOUT 60% REDUCTION IN ANNUALIZED
INFECTION RATE SEEN IN MAVORIXAFOR ARM VERSUS. PLACEBO IN STUDY
    * X4 PHARMACEUTICALS - OVER 75% REDUCTION IN PERCENTAGE OF
INDIVIDUALS EXPERIENCING SEVERE INFECTIONS IN MAVORIXAFOR GROUP
VERSUS. PLACEBO GROUP IN STUDY
    * X4 PHARMACEUTICALS - OVER 70% REDUCTION IN MEAN TOTAL DAYS
WITH
INFECTIONS (2 WEEKS ON MAVORIXAFOR TREATMENT VERSUS.7 WEEKS ON
PLACEBO) IN STUDY

Source text for Eikon:  ID:nGNX6N3x6F 
Further company coverage:  XFOR.O 

 ((Reutersbriefs@thomsonreuters.com;))